Paul M P Van Bergen En Henegouwen

List of Publications by Year
in descending order

108 papers	7,837 citations	38742 50 h-index	51608 86 g-index
110 all docs	110 docs citations	110 times ranked	10580 citing authors

#	Article	IF	Citations
1	Novel VHH-Based Tracers with Variable Plasma Half-Lives for Imaging of CAIX-Expressing Hypoxic Tumor Cells. Molecular Pharmaceutics, 2022, 19, 3511-3520.	4.6	6
2	Structural insights into the non-inhibitory mechanism of the anti-EGFR EgB4 nanobody. BMC Molecular and Cell Biology, 2022, 23, 12.	2.0	5
3	Multifaceted Activities of Seven Nanobodies against Complement C4b. Journal of Immunology, 2022, 208, 2207-2219.	0.8	5
4	Nanobody-Targeted Photodynamic Therapy: Nanobody Production and Purification. Methods in Molecular Biology, 2022, 2451, 481-493.	0.9	0
5	Single Domain Antibodies as Carriers for Intracellular Drug Delivery: A Proof of Principle Study. Biomolecules, 2021, 11, 927.	4.0	2
6	Nanobody-targeted photodynamic therapy for the treatment of feline oral carcinoma: a step towards translation to the veterinary clinic. Nanophotonics, 2021, 10, 3075-3087.	6.0	6
7	Homogeneous tumor targeting with a single dose of HER2-targeted albumin-binding domain-fused nanobody-drug conjugates results in long-lasting tumor remission in mice. Theranostics, 2021, 11, 5525-5538.	10.0	33
8	Generation of a nanobody against HER2 tyrosine kinase using phage display library screening for HER2-positive breast cancer therapy development. Protein Engineering, Design and Selection, 2021, 34, .	2.1	10
9	Dual Targeting of Endothelial and Cancer Cells Potentiates In Vitro Nanobody-Targeted Photodynamic Therapy. Cancers, 2020, 12, 2732.	3.7	12
10	Siteâ€specific functionality and tryptophan mimicry of lipidation in tetraspanin CD9. FEBS Journal, 2020, 287, 5323-5344.	4.7	10
11	Development of in vitro-grown spheroids as a 3D tumor model system for solid-state NMR spectroscopy. Journal of Biomolecular NMR, 2020, 74, 401-412.	2.8	9
12	Acute cellular and vascular responses to photodynamic therapy using EGFR-targeted nanobody-photosensitizer conjugates studied with intravital optical imaging and magnetic resonance imaging. Theranostics, 2020, 10, 2436-2452.	10.0	32
13	Nanobody-targeted photodynamic therapy induces significant tumor regression of trastuzumab-resistant HER2-positive breast cancer, after a single treatment session. Journal of Controlled Release, 2020, 323, 269-281.	9.9	49
14	Case Report: An EGFR-Targeted 4-1BB-agonistic Trimerbody Does Not Induce Hepatotoxicity in Transgenic Mice With Liver Expression of Human EGFR. Frontiers in Immunology, 2020, 11, 614363.	4.8	5
15	Implications for tetraspanin-enriched microdomain assembly based on structures of CD9 with EWI-F. Life Science Alliance, 2020, 3, e202000883.	2.8	15
16	VHH-Photosensitizer Conjugates for Targeted Photodynamic Therapy of Met-Overexpressing Tumor Cells. Antibodies, 2019, 8, 26.	2.5	28
17	Imaging of Tumor Spheroids, Dual-Isotope SPECT, and Autoradiographic Analysis to Assess the Tumor Uptake and Distribution of Different Nanobodies. Molecular Imaging and Biology, 2019, 21, 1079-1088.	2.6	22
18	A small protein probe for correlated microscopy of endogenous proteins. Histochemistry and Cell Biology, 2018, 149, 261-268.	1.7	16

#	Article	IF	Citations
19	ATTACK, a novel bispecific T cell-recruiting antibody with trivalent EGFR binding and monovalent CD3 binding for cancer immunotherapy. OncoImmunology, 2018, 7, e1377874.	4.6	56
20	A bispecific nanobody approach to leverage the potent and widely applicable tumor cytolytic capacity of VÎ³9VÎ´2-T cells. OncoImmunology, 2018, 7, e1375641.	4.6	61
21	The architecture of EGFRâ€™s basal complexes reveals autoinhibition mechanisms in dimers and oligomers. Nature Communications, 2018, 9, 4325.	12.8	71
22	Adaptive Resistance to EGFR-Targeted Therapy by Calcium Signaling in NSCLC Cells. Molecular Cancer Research, 2018, 16, 1773-1784.	3.4	9
23	Class <scp>III</scp> antiarrhythmic drugs amiodarone and dronedarone impair <scp>K_{IR}</scp>2.1 backward trafficking. Journal of Cellular and Molecular Medicine, 2017, 21, 2514-2523.	3.6	12
24	Probing cytoskeletal modulation of passive and active intracellular dynamics using nanobody-functionalized quantum dots. Nature Communications, 2017, 8, 14772.	12.8	65
25	Prevention of VÎ³9VÎ´2 T Cell Activation by a VÎ³9VÎ´2 TCR Nanobody. Journal of Immunology, 2017, 198, 308-317.	0.8	9
26	Antibody or Antibody Fragments: Implications for Molecular Imaging and Targeted Therapy of Solid Tumors. Frontiers in Immunology, 2017, 8, 1287.	4.8	181
27	Generation and characterization of CD1dâ€specific singleâ€domain antibodies with distinct functional features. Immunology, 2016, 149, 111-121.	4.4	14
28	Highly specific and potently activating VÎ³9VÎ´2-T cell specific nanobodies for diagnostic and therapeutic applications. Clinical Immunology, 2016, 169, 128-138.	3.2	29
29	EGFR targeted nanobodyâ€"photosensitizer conjugates for photodynamic therapy in a pre-clinical model of head and neck cancer. Journal of Controlled Release, 2016, 229, 93-105.	9.9	132
30	High affinity nanobodies against human epidermal growth factor receptor selected on cells by<i>E. coli</i>display. MAbs, 2016, 8, 1286-1301.	5.2	28
31	Nanobodies and Antibodies for Duplexed EGFR/HER2 Immunoassays Using Terbium-to-Quantum Dot FRET. Chemistry of Materials, 2016, 28, 8256-8267.	6.7	51
32	EGFR Dynamics Change during Activation in Native Membranes as Revealed by NMR. Cell, 2016, 167, 1241-1251.e11.	28.9	153
33	Time-gated FRET nanoassemblies for rapid and sensitive intra- and extracellular fluorescence imaging. Science Advances, 2016, 2, e1600265.	10.3	56
34	Optical imaging of pre-invasive breast cancer with a combination of VHHs targeting CAIX and HER2 increases contrast and facilitates tumour characterization. EJNMMI Research, 2016, 6, 14.	2.5	43
35	Hypoxia-Targeting Fluorescent Nanobodies for Optical Molecular Imaging of Pre-Invasive Breast Cancer. Molecular Imaging and Biology, 2016, 18, 535-544.	2.6	54
36	PEGylated and targeted extracellular vesicles display enhanced cell specificity and circulation time. Journal of Controlled Release, 2016, 224, 77-85.	9.9	402

#	Article	IF	Citations
37	Nanobody-based cancer therapy of solid tumors. Nanomedicine, 2015, 10, 161-174.	3.3	204
38	Identification of a novel MET mutation in high-grade glioma resulting in an auto-active intracellular protein. Acta Neuropathologica, 2015, 130, 131-144.	7.7	43
39	Resolving bundled microtubules using anti-tubulin nanobodies. Nature Communications, 2015, 6, 7933.	12.8	174
40	Nanobody-targeted photodynamic therapy for oncology. Photodiagnosis and Photodynamic Therapy, 2015, 12, 339.	2.6	2
41	Membrane domain formationÃ¢â,¬â€a key factor for targeted intracellular drug delivery. Frontiers in Physiology, 2014, 5, 462.	2.8	3
42	Nanobodies and Nanocrystals: Highly Sensitive Quantum Dotâ€Based Homogeneous FRET Immunoassay for Serumâ€Based EGFR Detection. Small, 2014, 10, 734-740.	10.0	98
43	Targeting hepatocyte growth factor receptor (Met) positive tumor cells using internalizing nanobody-decorated albumin nanoparticles. Biomaterials, 2014, 35, 601-610.	11.4	72
44	Bispecific antibody platforms for cancer immunotherapy. Critical Reviews in Oncology/Hematology, 2014, 92, 153-165.	4.4	78
45	Nanobodyâ€"photosensitizer conjugates for targeted photodynamic therapy. Nanomedicine: Nanotechnology, Biology, and Medicine, 2014, 10, 1441-1451.	3.3	76
46	Membrane rearrangements mediated by coronavirus nonstructural proteins 3 and 4. Virology, 2014, 458-459, 125-135.	2.4	128
47	Abstract 4935: Hypoxia targeting fluorescent nanobodies for optical molecular imaging of preinvasive breast cancer. , 2014, , .		0
48	Rapid optical imaging of human breast tumour xenografts using anti-HER2 VHHs site-directly conjugated to IRDye 800CW for image-guided surgery. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 1718-1729.	6.4	109
49	Inhibiting the clathrin-mediated endocytosis pathway rescues KIR2.1 downregulation by pentamidine. Pflugers Archiv European Journal of Physiology, 2013, 465, 247-259.	2.8	23
50	Inhibition of Tumor Growth by Targeted Anti-EGFR/IGF-1R Nanobullets Depends on Efficient Blocking of Cell Survival Pathways. Molecular Pharmaceutics, 2013, 10, 3717-3727.	4.6	26
51	Analysis of EGF Receptor Oligomerization by Homo-FRET. Methods in Cell Biology, 2013, 117, 305-321.	1.1	9
52	Molecular imaging with a fluorescent antibody targeting carbonic anhydrase IX can successfully detect hypoxic ductal carcinoma in situ of the breast. Breast Cancer Research and Treatment, 2013, 140, 263-272.	2.5	21
53	Structural Evaluation of EGFR Inhibition Mechanisms for Nanobodies/VHH Domains. Structure, 2013, 21, 1214-1224.	3.3	185
54	Targeting tumors with nanobodies for cancer imaging and therapy. Journal of Controlled Release, 2013, 172, 607-617.	9.9	172

#	Article	IF	Citations
55	Nanobody-albumin nanoparticles (NANAPs) for the delivery of a multikinase inhibitor 17864 to EGFR overexpressing tumor cells. Journal of Controlled Release, 2013, 165, 110-118.	9.9	88
56	Amphiregulin Enhances Regulatory T Cell-Suppressive Function via the Epidermal Growth Factor Receptor. Immunity, 2013, 38, 275-284.	14.3	324
57	EGFR endocytosis requires its kinase activity and N-terminal transmembrane dimerization motif. Journal of Cell Science, 2013, 126, 4900-12.	2.0	52
58	Therapeutic stem cells expressing variants of EGFR-specific nanobodies have antitumor effects. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 16642-16647.	7.1	70
59	Rapid Visualization of Human Tumor Xenografts through Optical Imaging with a Near-Infrared Fluorescent Antiâ€“Epidermal Growth Factor Receptor Nanobody. Molecular Imaging, 2012, 11, 7290.2011.00025.	1.4	152
60	A novel method to quantify IRDye800CW fluorescent antibody probes ex vivo in tissue distribution studies. EJNMMI Research, 2012, 2, 50.	2.5	49
61	Tumor-targeted Nanobullets: Anti-EGFR nanobody-liposomes loaded with anti-IGF-1R kinase inhibitor for cancer treatment. Journal of Controlled Release, 2012, 159, 281-289.	9.9	83
62	Rapid visualization of human tumor xenografts through optical imaging with a near-infrared fluorescent anti-epidermal growth factor receptor nanobody. Molecular Imaging, 2012, 11, 33-46.	1.4	88
63	Facile labelling of an anti-epidermal growth factor receptor Nanobody with 68Ga via a novel bifunctional desferal chelate for immuno-PET. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 753-763.	6.4	87
64	Homoâ€FRET Imaging as a Tool to Quantify Protein and Lipid Clustering. ChemPhysChem, 2011, 12, 475-483.	2.1	82
65	A biparatopic antiâ€EGFR nanobody efficiently inhibits solid tumour growth. International Journal of Cancer, 2011, 129, 2013-2024.	5.1	210
66	ErbB1 dimerization is promoted by domain co-confinement and stabilized by ligand binding. Nature Structural and Molecular Biology, 2011, 18, 1244-1249.	8.2	245
67	Enhancement of Polymeric Immunoglobulin Receptor Transcytosis by Biparatopic VHH. PLoS ONE, 2011, 6, e26299.	2.5	20
68	Downregulation of EGFR by a novel multivalent nanobody-liposome platform. Journal of Controlled Release, 2010, 145, 165-175.	9.9	117
69	Ligand-induced EGF Receptor Oligomerization Is Kinase-dependent and Enhances Internalization. Journal of Biological Chemistry, 2010, 285, 39481-39489.	3.4	98
70	EGF induces rapid reorganization of plasma membrane microdomains. Communicative and Integrative Biology, 2009, 2, 213-214.	1.4	9
71	Eps15: a multifunctional adaptor protein regulating intracellular trafficking. Cell Communication and Signaling, 2009, 7, 24.	6.5	66
72	High Cytotoxicity of Cisplatin Nanocapsules in Ovarian Carcinoma Cells Depends on Uptake by Caveolae-Mediated Endocytosis. Clinical Cancer Research, 2009, 15, 1259-1268.	7.0	43

#	Article	IF	Citations
73	Homo-FRET Imaging Enables Quantification of Protein Cluster Sizes with Subcellular Resolution. Biophysical Journal, 2009, 97, 2613-2622.	0.5	140
74	Integrated fluorescence and transmission electron microscopy. Journal of Structural Biology, 2008, 164, 183-189.	2.8	158
75	EGF induces coalescence of different lipid rafts. Journal of Cell Science, 2008, 121, 2519-2528.	2.0	132
76	Confocal time-resolved fluorescence anisotropy imaging. , 2007, , .		2
77	Imaging of protein cluster sizes by means of confocal time-gated fluorescence anisotropy microscopy. Optics Express, 2007, 15, 6934.	3.4	51
78	Efficient inhibition of EGFR signalling and of tumour growth by antagonistic anti-EGFR Nanobodies. Cancer Immunology, Immunotherapy, 2007, 56, 303-317.	4.2	315
79	A regulated interaction with the UIM protein Eps15 implicates parkin in EGF receptor trafficking and PI(3)Kâ€"Akt signalling. Nature Cell Biology, 2006, 8, 834-842.	10.3	325
80	Molecular biology of epidermal growth factor receptor inhibition for cancer therapy. Expert Opinion on Biological Therapy, 2006, 6, 605-617.	3.1	54
81	The blood-brain barrier transmigrating single domain antibody: mechanisms of transport and antigenic epitopes in human brain endothelial cells. Journal of Neurochemistry, 2005, 95, 1201-1214.	3.9	176
82	Ubiquilin recruits Eps15 into ubiquitin-rich cytoplasmic aggregates via a UIM-UBL interaction. Journal of Cell Science, 2005, 118, 4437-4450.	2.0	57
83	Phosphatidylinositol 4-KinaseÎ² Is Critical for Functional Association of rab11 with the Golgi Complex. Molecular Biology of the Cell, 2004, 15, 2038-2047.	2.1	147
84	Sorting of Ligand-activated Epidermal Growth Factor Receptor to Lysosomes Requires Its Actin-binding Domain. Journal of Biological Chemistry, 2004, 279, 11562-11569.	3.4	20
85	A Ubiquitin-interacting Motif (UIM) Is Essential for Eps15 and Eps15R Ubiquitination. Journal of Biological Chemistry, 2002, 277, 30746-30753.	3.4	88
86	VIIa/Tissue Factor Interaction Results in a Tissue Factor Cytoplasmic Domain-independent Activation of Protein Synthesis, p70, and p90 S6 Kinase Phosphorylation. Journal of Biological Chemistry, 2002, 277, 27065-27072.	3.4	47
87	Nuclear localization of phosphatidylinositol 4-kinase Î². Journal of Cell Science, 2002, 115, 1769-1775.	2.0	50
88	Factor VIIa/Tissue Factor-induced Signaling via Activation of Src-like Kinases, Phosphatidylinositol 3-Kinase, and Rac. Journal of Biological Chemistry, 2000, 275, 28750-28756.	3.4	85
89	Protein Kinase CÎ¶ Is a Negative Regulator of Protein Kinase B Activity. Journal of Biological Chemistry, 1999, 274, 8589-8596.	3.4	118
90	Sequence-specific 1H, 13C and 15N assignment and secondary structure of the apo EH2 domain of mouse Eps15. Journal of Biomolecular NMR, 1999, 14, 97-98.	2.8	1

#	Article	IF	Citations
91	Cyclooxygenase-dependent signalling: molecular events and consequences. FEBS Letters, 1999, 445, 1-5.	2.8	43
92	The EH1 Domain of Eps15 Is Structurally Classified as a Member of the S100 Subclass of EF-Hand-Containing Proteinsâ€. Biochemistry, 1999, 38, 11271-11277.	2.5	32
93	Sequence-specific 1H, 13C and 15N assignment of the EH1 domain of mouse Eps15. Journal of Biomolecular NMR, 1998, 12, 465-466.	2.8	2
94	Activation of Rho-Dependent Cell Spreading and Focal Adhesion Biogenesis by the v-Crk Adaptor Protein. Molecular and Cellular Biology, 1998, 18, 3044-3058.	2.3	71
95	A Function for EGF-Induced Eps15 Ubiquitination in Endocytosis. , 1998, , 85-94.		1
96	Association and Colocalization of Eps15 with Adaptor Protein-2 and Clathrin. Journal of Cell Biology, 1997, 136, 811-821.	5.2	118
97	Epidermal Growth Factor Induces Ubiquitination of Eps15. Journal of Biological Chemistry, 1997, 272, 14013-14016.	3.4	100
98	The Actin Binding Domain of the Epidermal Growth Factor Receptor Is Required for EGF-Stimulated Tissue Invasion. Experimental Cell Research, 1997, 234, 521-526.	2.6	23
99	Identification of an intracellular domain of the EGF receptor required for high-affinity binding of EGF. FEBS Letters, 1997, 410, 265-268.	2.8	20
100	A function for Eps15 in EGF-receptor endocytosis?. , 1997, , 151-161.		0
101	Dissociation of NGF Induced Signal Transduction from Neurite Elongation by Expression of a Mutant Adaptor Protein v-Crk in PC12 Cells. Molecular and Cellular Neurosciences, 1996, 8, 157-170.	2.2	14
102	Maximal epidermal growth-factor-induced cytosolic phospholipase A2 activation in vivo requires phosphorylation followed by an increased intracellular calcium concentration. Biochemical Journal, 1996, 313, 91-96.	3.7	59
103	The epidermal growth factor.. Cell Biology International, 1995, 19, 413-430.	3.0	250
104	Epidermal growth factor induces serine phosphorylation of actin. FEBS Letters, 1995, 357, 251-254.	2.8	35
105	Morphological and biochemical evidence for partial nuclear localization of annexin 1 in endothelial cells. Biochemical and Biophysical Research Communications, 1992, 186, 432-439.	2.1	40
106	Heat shock-induced redistribution of a 160-kDa nuclear matrix protein. Experimental Cell Research, 1992, 202, 243-251.	2.6	11
107	Membrane vesicles of A431 cells contain one class of epidermal growth factor binding sites. Biochimica Et Biophysica Acta - Molecular Cell Research, 1990, 1052, 453-460.	4.1	15
108	Heat shock gene expression and cytoskeletal alterations in mouse neuroblastoma cells. Experimental Cell Research, 1987, 171, 367-375.	2.6	38